Weekly briefings on funding, launches, leadership moves and hiring signals across life sciences and industrial markets, from the QP Group specialists who work in them every day.
Funding, launches, leadership moves and hiring signals across the companies building the future of science and healthcare.
Infrastructure funding, contractor consolidation, project awards and leadership moves across US construction and manufacturing.
The stories that mattered last week, across every market we cover.
FHIR-based prior auth now covers athenahealth's 180,000+ clinicians. In September, over 70% of Humana requests needed no extra input from practice staff.
Read the full story →The 15-year insider who led Natera into oncology takes over from Steve Chapman. Same day: Q3 revenue up 34.1% and 2026 guidance raised by $140M at the midpoint.
Read the full story →Advanced Drainage Systems grew Q2 sales 4.6% to $889.4M, mostly from its NDS acquisition, and cut its full-year sales range as housing slows. Non-residential work, including data centers, is up 10% this year.
Read the full story →Metering customers move to ZENNER USA, costing about $26M one-off for a 100-140bps margin lift. FY26 adjusted EBITDA rose 14.1% to $372.2M.
Read the full story →Total US construction spending fell 1.9% in September, but data centres jumped another 8.6%. ABC expects the gains to favour bigger contractors.
Read the full story →Software revenue rose 11% while services slipped 2%. It has also hired DocuSign's former CTO, Grant Peterson, as Chief Product Officer.
Read the full story →Ultragenyx is cutting about 20% of staff, to roughly 1,000, and Agios is removing more than 100 R&D roles, over 35% of its research headcount. Avidity, now part of Novartis, filed a WARN notice for 40 jobs.
Read the full story →Q3 revenue rose 22% to $1.7B and backlog stands at $20.4B. Data centres are 0.2% of the book, and the CEO says they won't be a focus.
Read the full story →Austedo, Ajovy and Uzedy made about $1.1bn in Q3 while group revenue fell 2%. Outlook raised for all three, and a long-acting olanzapine is about to launch.
Read the full story →Adjusted EBITDA hit €629m, but Evonik also booked €313m to extend Evonik Tailor Made, with 3,200 more job cuts planned for 2027–2029.
Read the full story →Sofinnova and RA Capital co-led the Oxford spinout's Series A. Its G6B antibody, ATX-011, goes after the cells that start the disease and is expected in the clinic in the first half of 2028.
Read the full story →Construction lost 3,000 jobs in October, its first drop since February. Nonresidential contractors added 13,300, while residential builders and subs shed 16,400. Nearly half of contractors plan to add staff in the next six months.
Read the full story →Read any newsletter in full.
10 Nov 2026 · Digital Health & Healthcare AI
10 Nov 2026 · Genomics & Diagnostics
10 Nov 2026 · HDPE Pipe
10 Nov 2026 · Waterworks
10 Nov 2026 · MEP
10 Nov 2026 · Life Science Software
Pick the markets you care about. Each is a three-minute weekly read, from the QP Group specialist for that market. No spam, one-click unsubscribe.
